更强的胆固醇治疗可显著减少冠状动脉斑块,新临床试验发现
Stronger cholesterol treatment shrinks more plaque in heart arteries, new clinical trial finds
一项名为 FLOWPROMOTE 的随机临床试验发现,更强的降胆固醇治疗可显著减少冠状动脉斑块。与标准治疗相比,组合疗法使斑块体积减少21.1%,而非钙化斑块减少28.2%。研究显示斑块并非不可逆转,但需进一步研究确认其对心血管事件的影响。
研究显示更强的降胆固醇治疗可显著减少冠状动脉斑块,为治疗冠心病提供了新策略。
Atherosclerosis is a condition in which cholesterol and fat gradually accumulate inside the walls of medium and large arteries, forming a sticky deposit called plaque. As these deposits grow, they narrow the arteries, restricting the flow of oxygen-rich blood to vital tissues and organs. Over time, this buildup can lead to ischemic heart disease (IHD) or stroke. In a recent randomized clinical trial called FLOWPROMOTE, researchers present a strategy to reverse atherosclerosis partially.
They tested whether aggressively lowering bad cholesterol in newly diagnosed patients using cholesterol-lowering statins can shrink and reverse plaque buildup in heart arteries. Over an 18-month treatment period, participants either took atorvastatin 40 mg daily, a standard high-dose statin, or rosuvastatin 40 mg plus ezetimibe 10 mg daily, a stronger statin combined with a medicine that blocks cholesterol absorption in the gut.
Plaque buildup in the heart's arteries isn't necessarily a point of no return because bringing cholesterol levels down aggressively can actually make existing plaques shrink. With combination therapy, 90% of patients saw their plaque volume decrease, compared with 75% on standard treatment. The findings are published in JAMA Cardiology.
Testing the limit of statins
Lowering low-density lipoprotein cholesterol (LDL-C), also known as bad cholesterol, is a primary target of many drugs that target fat buildup in arteries. Several clinical trials have linked every 38.6 mg/dL drop in LDL with a 22% reduction in atherosclerotic cardiovascular disease or atherosclerosis, and a 25%–30% reduction in coronary artery disease.
Imaging studies have shown that cholesterol-lowering treatments can shrink plaque buildup in coronary arteries. However, these studies only reported very modest shrinkage of about 1% to 5%. So, the researchers wanted to know if this was the absolute limit of what medications could achieve, or if better strategies could produce more substantial reversal.
For FLOWPROMOTE, the researchers brought together 104 adults from Denmark with stable chest pain and significant coronary artery disease, confirmed by a coronary CT scan showing more than 50% artery narrowing and restricted blood flow.
None had previously taken statins. The participants were randomly split into two equal groups, with one receiving intensive treatment with atorvastatin alone and the other receiving more intensive treatment with rosuvastatin and ezetimibe.
To track changes in their arteries over time, all participants underwent noninvasive coronary CT angiography (CTA) at three points: before treatment began, at nine months, and again at 18 months.
Two drugs better than one
They found that more intensive combination therapy lowered LDL cholesterol by 65%, bringing average levels down from 127.4 mg/dL to just 42.5 mg/dL, compared with a 38% reduction with standard intensive therapy. The cholesterol reduction was accompanied by greater plaque regression. Total plaque volume shrank by 21.1% with combination therapy, compared with 13.6% with standard treatment.
-
Waterfall plots of changes in total plaque volume. Credit: JAMA Cardiology (2026). DOI: 10.1001/jamacardio.2026.4788 -
Waterfall plots of changes in noncalcified plaque volume at 18 months. Credit: JAMA Cardiology (2026). DOI: 10.1001/jamacardio.2026.4788
The difference was even greater for noncalcified plaque, the softer, fat-rich deposits more prone to rupture, which shrank by 28.2% versus 20%. Noncalcified plaque regressed in 51 out of 52 patients receiving combination therapy, compared with 39 people on standard treatment. Calcified plaque volume, however, increased modestly in both groups, which indicated plaque stabilization, where dangerous soft-core lipids are depleted and replaced by stable calcium deposits.
The results show that existing artery plaque is not necessarily permanent and can be reversed with aggressive cholesterol-lowering treatment, but only further investigation can tell whether the greater reduction translates into fewer cardiovascular events.
Written for you by our author Sanjukta Mondal, edited by Sadie Harley, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.
Publication details
Martin Bødtker Mortensen et al., Intensive vs More Intensive Lipid-Lowering Therapy and Plaque Regression in Statin-Naive Patients, JAMA Cardiology (2026). DOI: 10.1001/jamacardio.2026.4788
Journal information: JAMA Cardiology
Who's behind this story?
Sanjukta Mondal
Master's in Chemistry. Freelance science journalist and communicator. Published in Chemistry World, BioSpace, and The Hindu. Full profile →
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
© 2026 Science X Network
Citation: Stronger cholesterol treatment shrinks more plaque in heart arteries, new clinical trial finds (2026, November 5) retrieved 5 November 2026 from https://medicalxpress.com/news/2026-11-stronger-cholesterol-treatment-plaque-heart.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com